Sionna Therapeutics (NASDAQ:SION) Director Sells $18,149.70 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 606 shares of the stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $29.95, for a total value of $18,149.70. Following the transaction, the director directly owned 771,762 shares in the company, valued at $23,114,271.90. The trade was a 0.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total value of $1,989,099.45.

Sionna Therapeutics Stock Down 2.4%

Shares of SION stock opened at $31.93 on Friday. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $34.00. The stock’s 50-day moving average is $25.52 and its 200 day moving average is $18.51.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.27.

Analyst Upgrades and Downgrades

SION has been the subject of a number of research analyst reports. Raymond James Financial initiated coverage on Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price target for the company. Jones Trading initiated coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price target for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada began coverage on Sionna Therapeutics in a research note on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 price objective for the company. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SION. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics during the second quarter valued at approximately $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Sionna Therapeutics during the second quarter valued at approximately $45,000. Virtus Investment Advisers LLC purchased a new position in Sionna Therapeutics during the second quarter valued at approximately $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Sionna Therapeutics during the second quarter valued at approximately $117,000. Finally, New York State Common Retirement Fund purchased a new position in Sionna Therapeutics during the second quarter valued at approximately $118,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.